CERo Therapeutics (NASDAQ:CERO) Given Hold Rating at D. Boral Capital

D. Boral Capital reiterated their hold rating on shares of CERo Therapeutics (NASDAQ:CERO) in a report released on Tuesday morning,Benzinga reports.

CERO has been the topic of a number of other research reports. Maxim Group cut CERo Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, November 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of CERo Therapeutics in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, CERo Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $45.00.

CERo Therapeutics Stock Performance

Shares of NASDAQ:CERO opened at $0.06 on Tuesday. CERo Therapeutics has a 52-week low of $0.05 and a 52-week high of $572.00. The company has a market capitalization of $73,625.50, a P/E ratio of 0.00 and a beta of 0.30. The company has a 50-day simple moving average of $3.02 and a 200 day simple moving average of $7.02.

CERo Therapeutics (NASDAQ:CERO) last announced its quarterly earnings results on Friday, August 22nd. The company reported ($61.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($70.23) by $8.52.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in CERo Therapeutics stock. Armistice Capital LLC bought a new position in shares of CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 312,000 shares of the company’s stock, valued at approximately $228,000. Armistice Capital LLC owned approximately 5.80% of CERo Therapeutics as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 29.64% of the company’s stock.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.